James Chopas George's most recent trade in Apellis Pharmaceuticals Inc was a trade of 6,250 Common Stock done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 6,250 | 54,205 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 11,250 | 11,250 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 24.83 per share. | 17 Mar 2025 | 183 | 47,955 (0%) | 0% | 24.8 | 4,543 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 1,096 | 48,138 (0%) | 0% | 30.4 | 33,346 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 12,591 | 49,234 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 715 | 36,643 (0%) | 0% | 30.0 | 21,420 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 783 | 37,358 (0%) | 0% | 28.7 | 22,474 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 36.21 per share. | 16 Sep 2024 | 192 | 38,141 (0%) | 0% | 36.2 | 6,952 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 39.49 per share. | 03 Sep 2024 | 550 | 38,333 (0%) | 0% | 39.5 | 21,720 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 56.46 per share. | 15 Mar 2024 | 184 | 38,883 (0%) | 0% | 56.5 | 10,389 | Common Stock |
| Apellis Pharmaceuticals Inc | George Chopas James | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 22 Jan 2024 | 1,061 | 39,067 (0%) | 0% | 65.0 | 68,961 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 12,086 | 12,086 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Chopas James George | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 8,312 | 40,992 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James Chopas George | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 66.81 per share. | 16 Jan 2024 | 864 | 40,128 (0%) | 0% | 66.8 | 57,723 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 41.23 per share. | 31 Aug 2023 | 551 | 30,312 (0%) | 0% | 41.2 | 22,716 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 5,737 | 5,737 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 4,044 | 31,197 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.50 per share. | 21 Feb 2023 | 334 | 30,863 (0%) | 0% | 58.5 | 19,539 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. | 20 Jan 2023 | 919 | 27,153 (0%) | 0% | 52.1 | 47,834 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 15,114 | 15,114 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 9,621 | 28,072 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.00 per share. | 20 Oct 2022 | 130 | 18,451 (0%) | 0% | 58 | 7,540 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.84 per share. | 30 Aug 2022 | 558 | 18,581 (0%) | 0% | 58.8 | 32,833 | Common Stock |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 15,116 | 15,116 | - | - | Stock Option (right to buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 10,657 | 19,139 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | VP/Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2021 | 882 | 8,482 (0%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | James George Chopas | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2021 | 21,750 | 21,750 | - | - | Stock Option (right to buy) | |
| Apellis Pharmaceuticals Inc | James George Chopas | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2021 | 7,600 | 7,600 (0%) | 0% | 0 | Common Stock |